Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.0105042 on June 7, 2005

Published online before print June 7, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0105042v1
78/2/462    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theilgaard-Mönch, K.
Right arrow Articles by Borregaard, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theilgaard-Mönch, K.
Right arrow Articles by Borregaard, N.
(Journal of Leukocyte Biology. 2005;78:462-470.)
© 2005 by Society for Leukocyte Biology

Highly glycosylated {alpha}1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils

Kim Theilgaard-Mönch*, Lars C. Jacobsen*, Thomas Rasmussen{dagger}, Carsten U. Niemann*, Lene Udby*, Rehannah Borup{ddagger}, Maged Gharib§, Peter D. Arkwright, Adrian F. Gombart||, Jero Calafat**, Bo T. Porse{ddagger} and Niels Borregaard*,1

* The Granulocyte Research Laboratory, Department of Hematology, and
{ddagger} Section of Gene Therapy Research, Department of Clinical Biochemistry, Rigshospitalet, and
{dagger} Department of Hematology, Herlev Hospital, University of Copenhagen, Denmark,
§ Department of Hematology, Royal Manchester Children’s Hospital, United Kingdom;
Booth Hall Children’s Hospital, University of Manchester, United Kingdom;
|| Division of Hematology/Oncology, Cedars-Sinai Medical Center, Burns and Allan Research Institute, University of California, Los Angeles, School of Medicine; and
** Department of Cell Biology, The Netherlands Cancer Institute, Amsterdam

1 Correspondence: Department of Hematology-4042, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen-Ø, Denmark. E-mail: borregaard{at}rh.dk

{alpha}-1-Acid glycoprotein (AGP) is an acute-phase protein produced by hepatocytes and secreted into plasma in response to infection/injury. We recently assessed the transcriptional program of terminal granulocytic differentiation by microarray analysis of bone marrow (BM) populations highly enriched in promyelocytes, myelocytes/metamyelocytes (MYs), and BM neutrophils. These analyses demonstrated a transient, high mRNA expression of genuine secondary/tertiary granule proteins and AGP in MYs. In agreement with this, immunocytochemistry revealed the presence of AGP protein and the secondary granule protein lactoferrin in cells from the MY stage and throughout granulocytic differentiation. Immunoelectron microscopy demonstrated the colocalization of AGP and lactoferrin in secondary granules of neutrophils. This finding was substantiated by the failure to detect AGP and lactoferrin in blood cells from a patient with secondary/tertiary (specific) granule deficiency. In addition, Western blot analysis of subcellular fractions isolated from neutrophils revealed that neutrophil-derived AGP, localized in secondary granules, was abundant and highly glycosylated compared with endocytosed, plasma-derived AGP localized in secretory vesicles. Exocytosis studies further demonstrated a marked release of AGP and lactoferrin by activated neutrophils. Finally, induction of CCAAT/enhancer-binding protein (C/EBP)-{varepsilon} in a myeloid cell line was shown to increase AGP transcript levels, indicating that AGP expression in myeloid cells, like in hepatocytes, is partially regulated by members of the C/EBP family. Overall, these findings define AGP as a genuine secondary granule protein of neutrophils. Hence, neutrophils, which constitute the first line of defense, are likely to serve as the primary local source of AGP at sites of infection or injury.

Key Words: granulocytes • granule proteins • specific granule deficiency • acute-phase proteins • C/EBP{varepsilon}




This article has been cited by other articles:


Home page
FASEB J.Home page
P. Gunnarsson, L. Levander, P. Pahlsson, and M. Grenegard
The acute-phase protein {alpha}1-acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin-like lectins (Siglecs)
FASEB J, December 1, 2007; 21(14): 4059 - 4069.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
R. M. Novak, B. A. Donoval, P. J. Graham, L. A. Boksa, G. Spear, R. C. Hershow, H. Y. Chen, and A. Landay
Cervicovaginal Levels of Lactoferrin, Secretory Leukocyte Protease Inhibitor, and RANTES and the Effects of Coexisting Vaginoses in Human Immunodeficiency Virus (HIV)-Seronegative Women with a High Risk of Heterosexual Acquisition of HIV Infection
Clin. Vaccine Immunol., September 1, 2007; 14(9): 1102 - 1107.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. C. Jacobsen, K. Theilgaard-Monch, E. I. Christensen, and N. Borregaard
Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils
Blood, April 1, 2007; 109(7): 3084 - 3087.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Leukocyte Biology.